I D Stolyarov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1511542/publications.pdf

Version: 2024-02-01

		1684188	1372567	
13	91	5	10	
papers	citations	h-index	g-index	
20	20	20	128	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 67-72.	0.7	24
2	Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients. Acta Neurologica Scandinavica, 2018, 138, 408-416.	2.1	20
3	Characteristics of neurological and cognitive status in patients with multiple sclerosis in relation to the location and volumes of demyelination foci and the severity of brain atrophy. Neuroscience and Behavioral Physiology, 2009, 39, 35-38.	0.4	9
4	Pharmacokinetics of Levodopa/Carbidopa Delivered From Gastricâ€Retentive Extendedâ€Release Formulations in Patients With Parkinson's Disease. Journal of Clinical Pharmacology, 2012, 52, 1069-1077.	2.0	7
5	Measuring the distribution of plantar pressures during walking in patients with multiple sclerosis to evaluate treatment efficiency. Human Physiology, 2006, 32, 154-156.	0.4	4
6	The Role of Changes in Glucose Metabolism in the Brain in the Formation of Cognitive Impairments in Patients with Remitting and Secondary-Progressive Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2013, 43, 565-570.	0.4	3
7	Time course of changes in the development of gait disorders in multiple sclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2015, , 27.	1.2	3
8	Immunological reactivity in children with central nervous system injuries immunized with adsorbed diphtheria-tetanus anatoxin M and measles virus vaccines. Human Physiology, 2007, 33, 429-432.	0.4	0
9	Neuroimmunology: Theoretical and clinical aspects. Human Physiology, 2013, 39, 40-47.	0.4	0
10	Positron Emission Tomography Patterns in Cognitive Impairment in Patients with Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2014, 44, 513-516.	0.4	0
11	Potential of Positron Emission Tomography for Studies of the Mechanisms of Development of Multiple Sclerosis (published data and authors' results). Neuroscience and Behavioral Physiology, 2017, 47, 540-543.	0.4	0
12	Clinical and neurophysiological peculiarities of tumor-related epilepsy. Meditsinskii Akademicheskii Zhurnal, 2020, 20, 87-96.	0.2	0
13	Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic. Annals of Clinical and Experimental Neurology, 2022, 16, 70-77.	0.4	O